← FDA DRUG APPROVALS

FDA ANDA · ANDA074229

NADOLOL

Sponsor: HERITAGE PHARMA

APPLICATION
ANDA074229
TYPE
ANDA
ORIGINAL APPROVAL
1996-08-30
LATEST ACTION
2015-04-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NADOLOLDiscontinued
NADOLOL 40MG · TABLET · ORAL
NADOLOLDiscontinued
NADOLOL 20MG · TABLET · ORAL

Approval history

2015-04-16Labeling · Supplement 18AP
2015-04-16Labeling · Supplement 16AP
2015-04-16Labeling · Supplement 19 · standardAP
2002-07-29Manufacturing (CMC) · Supplement 7AP
2002-03-12Manufacturing (CMC) · Supplement 6AP
2001-07-31Manufacturing (CMC) · Supplement 4AP
2000-01-28Manufacturing (CMC) · Supplement 3AP
1998-04-06Manufacturing (CMC) · Supplement 1AP
1998-04-06Manufacturing (CMC) · Supplement 2AP
1996-08-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →